-
Semiconductor production relies on over 150 chemicals and more than 30 gases and minerals, with their quality and reliability playing a crucial role in the success of the manufacturing process.
-
Under the terms of the deal, Hansoh Pharma would also receive royalties on sales, and may co-promote or solely commercialize the drug in China subject to certain conditions, the companies said in the statement.
-
Prometheus's share price was at $114.01 when the New York Stock Exchange closed on April 14.
-
The number of cancer cases in India has increased dramatically over the last several years, with head and neck and oral cancers emerging as the leading forms of the illness in several states
-
Serum Institute's made-in-India HPV vaccine "CERVAVAC" was launched by Union Home Minister Amit Shah on January 24, in presence of the Pune-based firm's CEO Adar Poonawalla and Prakash Kumar Singh, its Director-Government and Regulatory Affairs.
-
A Merk spinoff, Organon is a global healthcare company, formed in 2021, that focuses on improving women's health. It works with government bodies and NGOs to educate women on family planning and contraception
-
A global healthcare company formed in 2021 through a spinoff from Merck, Organon focuses on improving the health of women. It works with government bodies and NGOs to educate women on family planning and contraception
-
Even as the third wave of COVID-19 pandemic subsides in India and most cases are reported to be mild, a new study has said that Molnupiravir, granted regulatory approval in the country in December, 2021 can be useful for patients at risk of disease progression.
-
Health professionals treating coronavirus patients across the country reported that the Covid antiviral drug has reduced hospitalisation by 30 to 50 percent, as well as severity of the disease.
-
A panel of US health advisers narrowly backed the benefits of a closely watched COVID-19 pill from Merck, setting the stage for a likely authorisation of the first drug that Americans could take at home to treat the virus.
-
Molnupiravir increases our armamentarium against COVID-19, but it cannot replace vaccines. So, then what’s the hype all about?
-
While Merck was the first to roll out its anti-COVID therapy, called molnupiravir, Pfizer has announced promising results of its own pill, called Paxlovid.
-
Currently all COVID-19 treatments used in the US require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.
-
The move, which could eventually lead to authorisation on the European market, comes two weeks after Merck applied for emergency use in the US of the anti-coronavirus drug.
-
Merck and its partner Ridgeback Biotherapeutic said they specifically asked the agency to grant emergency use for adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization. That is roughly the way COVID-19 infusion drugs are used.
-
Merck already has arrangements with eight Indian pharma companies to manufacture the drug and undoubtedly, all efforts will be made to make it more affordable than currently indicated
-
Merck executives told analysts Thursday they hope to launch the drug in either 2024 or 2025, and it has multi-billion dollar peak sales potential.
-
Swiss company Regeneron has signed with Cipla for exclusive distribution of its imported antibody cocktail in India.
-
Possibility of positive developments on the product pipeline front and restructuring initiatives can accelerate earnings growth for Lupin. We continue to believe this opportunity is more suitable for investors with high risk appetite and those who are ready to hold it long enough for the product pipeline to unfold
-
In the medium term, the focus is likely to be on the inhalation and biosimilar categories for Lupin, with scale-up in both US and European markets
-
"The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising," said William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a statement from the companies.
-
The announcement comes as the White House looks to speed the production of the single-dose vaccine.
-
Merck is now considering a range of options, both in the United States and around the world, mindful that anything it chooses to do would take months to bring to fruition, given the complexity of the manufacturing process
-
Frazier will continue to serve as executive chairman for Merck’s board of directors 'for a transition period to be determined by the board'.
-
Both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other COVID-19 vaccines, said Merck
